Head-to-head · WeighScore
Dr. Gillis' Wellness Center vs Omada Health
The verdict
Dr. Gillis' Wellness Center takes it — 67/100 to 55.6/100.
Dr. Gillis' Wellness Center grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Gillis' Wellness Center is a Maine-based clinic (Oakland) offering nationwide telehealth for GLP-1 weight loss. It prescribes semaglutide, tirzepatide, and retatrutide in both injectable and subli
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Dr. Gillis' Wellness Center | Omada Health |
|---|---|---|
| WeighScore | 67/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #169 | #435 |
| Semaglutide | $149/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #169 · C
Strengths
- Sublingual ODT tablets offered as needle-free alternative
- Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
- Transparent pricing: $150 starting dose, plans from $149/mo
- Led by board-certified physician/surgeon with 25+ years experience
- No contracts; flexible weekly, bi-weekly, or monthly cadence
Where it loses points
- Specific dose-tier pricing beyond starting plan not detailed
- Compounded vs brand not explicitly stated for all meds
- Smaller clinic vs national telehealth brands
- State licensing list not published
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.